ROIV NASDAQ
Credit Risk of going bust: lower than 90% of companies Debt: 0.4% of company value Bonds: none of note held by US funds details ▾
Total debt $107.2M against a stock market value of $26.39B.
Distance to default 13.63 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $53.6M (short-term plus half of long-term), stock volatility 45.2%; Altman Z'' 16.14. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
London, GL SW1H 0DB
GB
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Oren Ilan | A-Award | 810 | — | 2026-10-23 |
| Epperly Melissa B, | A-Award | 513 | — | 2026-10-23 |
| Epperly Melissa B, | F-InKind | 116 | $36.49 | 2026-10-23 |
| MOMTAZEE JAMES C | A-Award | 383 | — | 2026-10-23 |
| MOMTAZEE JAMES C | F-InKind | 77 | $36.49 | 2026-10-23 |